Skip to main content


2022 Oncology Biosimilar Guide to Patient Support Services

Sandoz One Source Support Services


Sandoz, a Novartis Division, offers the Sandoz One Source patient support program to assist patients while taking Zarxio or Ziextenzo (Table).

Sandoz One Source

This program offers several supportive resources for patients taking Zarxio or Ziextenzo, including a Commercial Co-Pay Program, in-home injection training, a Product Replacement Program, and a Patient Assistance Program.

Commercial Co-Pay Program

The Sandoz One Source Commercial Co-Pay Program supports eligible, commercially insured patients with their out-of-pocket costs for Zarxio or Ziextenzo, up to $10,000 annually. Patients may be eligible if they:

  • Have a prescription for Zarxio or Ziextenzo for an FDA-approved indication
  • Have commercial insurance
  • Do not participate in any state or federally funded grams, including, but not limited to, Medicare, Medicaid, Medigap, Veterans Administration, Department of Defense, or TRICARE.

In-Home Injection Training

Nurse trainers are available to visit your patient at their home to demonstrate proper administration of Zarxio or Ziextenzo and provide information on how to self-administer correctly. The nurse will also complete an Education Checklist at the end of the visit to help ensure the patient understands and is comfortable with self-administration. You or your patient can contact Sandoz One Source to request in-home injection training by calling 844-726-3691.

Product Replacement Program

Sandoz One Source offers a simple product replacement process for spoiled Zarxio or Ziextenzo under the following circumstances:

  • Product was mishandled, dropped, or broken
  • There was an admixture error
  • Product was inappropriately stored or refrigerated, or was frozen
  • Product was reconstituted but not administered due to an unforeseen reason.

Contact Sandoz One Source at 844-726-3691 to request a replacement product.

Novartis Patient Assistance Foundation

The Novartis Patient Assistance Foundation (NPAF) provides assistance to uninsured and underinsured patients who have been prescribed Zarxio or Ziextenzo. Patients may be eligible if they:

  • Are experiencing financial hardship and/or have no third-party insurance coverage
  • Reside in the United States
  • Have an income that meets the financial eligibility requirements
  • Have limited or no prescription coverage.

To learn more call 800-277-2254 or visit

Click here to learn more, or to enroll your patient in the Sandoz One Source program, or call 844-726-3691.

TABLE Sandoz Biosimilar Oncology Drugs

Patient support programs

Zarxio (filgrastim-sndz)
Patient support programs

Ziextenzo (pegfilgrastim-bmez)
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies who are receiving myelosuppressive anticancer drugs with a significant incidence of febrile neutropenia
Patient support programs

Zarxio (filgrastim-sndz) Indications

Decrease febrile neutropenia in patients using myelosuppressive anticancer drugs; reduce time to neutrophil recovery and duration of fever after induction or consolidation chemotherapy in patients with acute myeloid leukemia; reduce the duration of neutropenia and neutropenia-related sequelae in patients receiving myeloablative chemotherapy followed by bone marrow transplantation; mobilize autologous hematopoietic progenitor cells; reduce the incidence and duration of sequelae of severe neutropenia in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia